InvestorsHub Logo

rollin2nyte

05/12/16 12:36 AM

#199415 RE: Sixman #199404

Your missing the entire point of why new entrants into the market is a good thing. If you can't figure that out then you 're in the wrong investment.

And of course there are many competitors to Elite. You wanna know why? Because the modular formulation puts us in play with every subset of the ADF market.

Youlie

05/12/16 1:02 AM

#199420 RE: Sixman #199404

Goldmind is that you?

Couch

05/12/16 6:05 AM

#199425 RE: Sixman #199404

How many IR ADT opioids on the market? Zero - And 90% of all opioids prescribed are IR. It shows Nasrat has a first rate knowledge of how to proceed to capture as much of the market as fast as he can. Then he hires Eugene Pfeifer who specializes in FDA product approval, advertising, promotion, and compliance issues. I think Nasrat is already three steps ahead here. Then let's add in the modular plug and play component of Elite's abuse deterrent technology and I think Nasrat picks the 5 most prescribed opioids in the United States and puts out an 4-6 hour, 12 hr and 24 hr versions.

And in terms of undercutting the competition Elite has already had to do that with its existing generic pipeline has it not? I'll bet Nasrat does this with their branded ADT products as well as making generic ADT products of Pfizer's branded ADT products. This company will be a cash cow for years to come even if he works slow and steady. And Nasrat appears to be doing just the opposite.

NASDAQ2020

05/12/16 7:58 AM

#199440 RE: Sixman #199404

20 billion dollar pain market will be losing members as ADFs come on line and the non ADFs removed.
Looks like Elite has the IR ADF market cornered.
Nice being first !

NASDAQ2020

05/12/16 8:00 AM

#199441 RE: Sixman #199404

It demonstrates Elite has no competition in the IR ADF oxy market, thx.